High-mobility group protein B1 silencing promotes susceptibility of retinoblastoma cells to chemotherapeutic drugs through downregulating nuclear factor-κB

Chai,Yong; Xiao,Juhua; Zhang,Shouhua; Du,Yunyan; Luo,Zhipeng; Zhou,Xin; Huang,Kai

doi:10.3892/ijmm.2018.3379

High-mobility group protein B1 silencing promotes susceptibility of retinoblastoma cells to chemotherapeutic drugs through downregulating nuclear factor-κB

Authors:
- Yong Chai
- Juhua Xiao
- Shouhua Zhang
- Yunyan Du
- Zhipeng Luo
- Xin Zhou
- Kai Huang
View Affiliations

Affiliations: Department of Ophthalmology, Jiangxi Children's Hospital, Nanchang, Jiangxi 330006, P.R. China, Department of Ultrasound, Jiangxi Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. China, Department of Otolaryngology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi 330006, P.R. China, Department of Gastrointestinal Surgery, Jiangxi Provincial Cancer Hospital, Nanchang, Jiangxi 330029, P.R. China
Published online on: January 10, 2018 https://doi.org/10.3892/ijmm.2018.3379
Pages: 1651-1658

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effects of high-mobility group protein B1 (HMGB1) silencing on the susceptibility of retinoblastoma (RB) cells to chemotherapeutic drugs and the underlying molecular mechanisms. Western blot analysis revealed that vincristine (VCR), etoposide (ETO) and carboplatin (CBP) significantly increased the expression of HMGB1 in Weri‑Rb-1 and Y79 cells compared with the untreated control (P<0.01). siRNA HMGB1 and siRNA negative control (NC) were transfected to Y79 cells by Lipofectamine™ 2000 and, following VCR treatment, the expression of HMGB1 and nuclear factor-κB (NF-κB) was analyzed. siRNA HMGB1 transfection silenced HMGB1 expression. The cytotoxicity of VCR to cells with and without siRNA HMGB1 was investigated by methyl thiazolyl tetrazolium (MTT) assay. siRNA HMGB1 markedly reduced the IC50 value of VCR to RB cells through downregulating the expression of NF-κB, similar to pyrrolidinedithiocarbamate (PDTC). Moreover, following siRNA HMGB1, siRNA NC and ammonium PDTC treatment, the apoptosis of RB cells with VCR incubation was evaluated by Hoechst staining, and the expression of cleaved caspase-3, cleaved poly(ADP-ribose) polymerase (PARP), Beclin 1 and p62 were determined with western blot analysis. The LC3 puncta were determined with immunofluorescence assay. The results demonstrated that VCR treatment significantly downregulated the expression of cleaved caspase-3, cleaved PARP and p62, and upregulated the expression of Beclin 1 in RB cells (P<0.01). Similar to the NF-κB inhibitor PDTC, siRNA HMGB1 significantly promoted apoptosis and suppressed autophagy of VCR‑treated RB cells through reversing the effects of VCR on these signaling molecules (P<0.01). Therefore, HMGB1 silencing promoted the susceptibility of RB cells to chemotherapeutic drugs through downregulating NF-κB.

View Figures

View References

1	Zheng M, Wu H, Wang J, Jin G, Jiang W and Sha O: Progress of retinoblastoma pathogenesis. Anat Res. 37:223–228. 2015.In Chinese.
2	Li J and Bo L: Progress in therapy and research in retinoblastoma. J Clin Ophthalmol. 22:185–188. 2014.In Chinese.
3	Liu J and Zhu Y: Recent advances in retinoblastoma treatment. Recent Adv Ophthalmol. 33:91–94. 2013.In Chinese.
4	Manjandavida FP and Shields CL: The role of intravitreal chemotherapy for retinoblastoma. Indian J Ophthalmol. 63:141–145. 2015. View Article : Google Scholar : PubMed/NCBI
5	Huang J, Liu K, Song D, Ding M, Wang J, Jin Q and Ni J: Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells. Cancer Sci. 107:242–249. 2016. View Article : Google Scholar :
6	Li X, Wang S, Chen Y, Liu G and Yang X: miR-22 targets the 3′UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy. Tumour Biol. 35:6021–6028. 2014. View Article : Google Scholar : PubMed/NCBI
7	Naumnik W, Nilklińska W, Ossolińska M and Chyczewska E: Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol. 47:703–709. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ran X, Yang J, Liu C, Zhou P, Xiao L and Zhang K: MiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy. Int J Clin Exp Pathol. 8:6617–6626. 2015.PubMed/NCBI
9	Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, Fujii K, Ohmori H and Kuniyasu H: High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer. 49:741–751. 2013. View Article : Google Scholar
10	Hu Y, Yang L and Zhang C: HMGB1-a as potential target for therapy of hematological malignancies-review. J Exp Hematol. 24:560–564. 2014.In Chinese.
11	Cao Q, Liu Y and Ling C: Research progress of the correlation between HMGB1 and tumor. Chin Clin Oncol. 17:282–285. 2012.In Chinese.
12	Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, et al: Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol. 34:81–90. 2013. View Article : Google Scholar
13	Goodwin GH, Sanders C and Johns EW: A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem. 38:14–19. 1973. View Article : Google Scholar : PubMed/NCBI
14	Wang X, Xiang L, Li H, Chen P, Feng Y, Zhang J, Yang N, Li F, Wang Y, Zhang Q, et al: The role of HMGB1 signaling pathway in the development and progression of hepatocellular carcinoma: A review. Int J Mol Sci. 16:22527–22540. 2015. View Article : Google Scholar : PubMed/NCBI
15	Erlandsson Harris H and Andersson U: Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol. 34:1503–1512. 2004. View Article : Google Scholar : PubMed/NCBI
16	Singh MK, Singh L, Pushker N, Sen S, Sharma A, Chauhan FA and Kashyap S: Correlation of high mobility group box-1 protein (HMGB1) with clinicopathological parameters in primary retinoblastoma. Pathol Oncol Res. 21:1237–1242. 2015. View Article : Google Scholar : PubMed/NCBI
17	Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Lotze MT, et al: HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia. 25:23–31. 2011. View Article : Google Scholar
18	Zhang R, Li Y, Wang Z, Chen L, Dong X and Nie X: Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis. Tumour Biol. 36:8585–8592. 2015. View Article : Google Scholar : PubMed/NCBI
19	Prajoko YW and Aryandono T: Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer. Asian Pac J Cancer Prev. 15:595–598. 2014. View Article : Google Scholar
20	Endo F, Nishizuka SS, Kume K, Ishida K, Katagiri H, Ishida K, Sato K, Iwaya T, Koeda K and Wakabayashi G: A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines. PLoS One. 9:e901552014. View Article : Google Scholar
21	Wu Y, Fang W and Li Y: Mechanisms and reversing drugs of cancer multidrug resistance. Pharma Clin Res. 24:43–47. 2016.In Chinese.
22	Pan G and Yan L: Research advancement on mechanism of tumor multidrug resistance. Med Recapitulate. 15:1162–1164. 2009.In Chinese.
23	Liu K, Huang J, Xie M, Yu Y, Zhu S, Kang R, Cao L, Tang D and Duan X: MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy. 10:442–452. 2014. View Article : Google Scholar : PubMed/NCBI
24	Jiang Y and Zhang J and Zhang J: Progresses on autophagy and drug resistance of tumor. Life Sci Res. 19:62–67. 2015.In Chinese.